USA-based Northfield Laboratories has filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Bankruptcy Court for the District of Delaware.
The filing was made to facilitate the company's previously-announced plan to wind down its business operations and carry out an orderly disposition of its assets. The decision to file was made after an exhaustive review of alternative options and is seen as the most favorable means for the firm to continue its wind-down process and liquidate its remaining assets for the benefit of its creditors and other interested parties.
The company expects to file with the bankruptcy court a liquidating plan and related disclosure statement. Northfield says that it will seek approval of the Plan as expeditiously as practicable pursuant to relevant notice requirements, the Bankruptcy Code and applicable law and procedures.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze